Brivaracetam
Unverricht-Lundborg Syndrome
UCB Pharma SASmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Unverricht-Lundborg Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Brv UCB Pharma | Phase 3 | BB |
Human Immunoglobulins Azienda Socio Sanitaria Territoriale di Mantova | Phase 3 | B |
Ropinirole University of Turku | Phase 2 | CCC |
Same molecule, other indications
Brivaracetam is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →